RegulationOrphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Special Review Project (China)

Structure/Sequence

Molecular FormulaC22H19FN4O2

InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-N

CAS Registry1616493-44-7

261

Clinical Trials associated with Chidamide

NCT06570447

/ RecruitingPhase 2IIT

An Open-label, Single-arm, Single-center, Phase II Clinical Trial of Glofitamab Combination With Chidamide in Patients With Recurrent and Refractory Diffuse Large B-Cell Lymphoma

An open-label, single-arm, single-center, phase II clinical trial to evaluate the feasibility, efficacy and safety of Glofitamab Combination with chidamide in patients with recurrent/refractory diffuse large B-cell lymphoma.

Start Date15 May 2025

Sponsor / Collaborator

Tianjin Medical University Cancer Institute and Hospital

NCT06858956

/ Not yet recruitingNot ApplicableIIT

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.

Start Date01 Mar 2025

Sponsor / Collaborator

Cancer Hospital Chinese Academy of Medical Sciences

ChiCTR2500096832

/ SuspendedPhase 2IIT

Cadonilimab and Chemotherapy combined with Chidamide as first-line treatment for advanced and metastatic gastric cancer (G-alaCtiCa/SCOG-G004): A two-arm, exploratory trial

Start Date17 Feb 2025

Sponsor / Collaborator

The First Affiliated Hospital of Soochow University

100 Clinical Results associated with Chidamide

100 Translational Medicine associated with Chidamide

100 Patents (Medical) associated with Chidamide

2,713

Literatures (Medical) associated with Chidamide

01 Jul 2025·JOURNAL OF HAZARDOUS MATERIALS

Removal efficiency and adaptive response mechanisms of microalgal-bacterial granular sludge in treating chloramphenicol-laden wastewater

Article

Author: Zhang, Xiaoyuan ; Ji, Bin ; Liu, Yu ; Li, Anjie ; Bai, Yang ; Chen, Bingheng ; Liang, Hua

Efficient and eco-friendly technologies for removing antibiotic pollutants like chloramphenicol (CAP) from wastewater are becoming increasingly important. Among these, microalgal-bacterial granular sludge (MBGS) represents a promising green biotechnology capable of tackling such contaminants. However, the interactions between CAP and MBGS, as well as how CAP influences the community structure and function of MBGS, have not yet been fully understood. This study investigated the effectiveness of the MBGS system in CAP removal and examined microbial responses to CAP exposure. Our findings indicate that MBGS exhibits remarkable adaptability to CAP, altering its microbial characteristics to mitigate CAP toxicity while maintaining the efficacy of pollutant removal. Notably, there was a significant increase in key microorganisms such as Hydrogenophaga, Polaromonas, and Acidovorax. Additionally, the prevalence of resistance genes cmlA8, floR, catB and cfr under CAP exposure suggests adaptive mechanisms likely involving efflux pumps, CAP acetyltransferase B and ribosomal RNA methyltransferase. CAP degradation appears to proceed via the amide bond hydrolase EstDL136, thereby reducing its toxicity and producing less harmful byproducts such as 2,2-dichloroacetic acid. This study provides new insights into how CAP affects MBGS communities and identifies the mechanisms for CAP degradation, offering valuable insights that MBGS could serve as an effective and environmentally sustainable technology for the treatment of wastewater containing antibiotic pollutants.

01 May 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Exploring cellulose-derived esters/curcumin materials: Synthesis, characterization, and biological assay in zebrafish model

Article

Author: Cristovan, Fernando Henrique ; Duarte, Clodoaldo Junior Aires ; da Silva, Naiton Martins ; Lima, Samuel Oliveira ; Valadares, Lorrany Pereira de Assis ; Machado, Monica Ferreira Rodrigues ; Lopes, Mariana Silva ; Arantes, Tatiane Moraes ; Gabriel, Arthur Martins ; de Oliveira, Gildiberto Mendonça

A crucial challenge for science is to transform agricultural production waste into high-value-added materials suitable for multiple applications, such as in the construction of electronic devices or the medical field, such as scaffolds for tissue engineering or controlled drug release. Thus, we used polymers derived from cellulose from corn husks, from local agricultural production. In this study, we evaluated the physical-chemical and biological properties of polymeric films of cellulose acetate phthalate (CAP) and cellulose triacetate (CTA), and their blends with curcumin (CUR). The ester cellulose derivatives were synthesized using cellulose and its chemical synthesis was confirmed by Fourier Transform Infrared (FT-IR) spectroscopy. The ester cellulose derivatives polymeric were processed by the casting technique in film forms and characterized by thermogravimetric analysis and differential scanning calorimetry. CAP and CTA thermal analysis shows that they are less stable at higher temperatures than unmodified cellulose. The embryotoxicity, teratogenicity, and neurotoxicity of the prepared materials were evaluated in vivo using the Zebrafish assay, where curcumin showed that high concentrations of this molecule affect the survival rate of zebrafish embryos. However, the assays done with CTA and CAP did not present a significant effect on this parameter. The tests performed with CAP and its blends with curcumin (CTA/Cur and CAP/Cur) did not indicate neurotoxicity or cardiotoxicity. However, an increased heart rate was observed in zebrafish embryos exposed to pure CTA.

01 May 2025·APPETITE

N-methyl-D-aspartate glutamate receptor blockade inhibits the sensitization of sodium appetite independent of alterations in salt palatability

Article

Author: Andrade, Carina A F ; Pereira, Emilson D ; Menani, José V ; Zenatti, Aline A ; De Luca, Laurival A ; de Paula, Patrícia M

The intraperitoneal injection (ip) of N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine, MK-801, blocks sodium appetite sensitization in rats. Therefore, NMDA receptors seem important for ingestive behavioral adaptations to episodic or chronic periods of dehydration and salt depletion. Orofacial somatic motor responses to intraoral infusion of salt, in a salt taste reactivity test, can be an index of salt palatability. The objective of the present study was to investigate whether ip injection of MK-801 (0.15 mg/kg) alters orofacial responses to intraoral salt (0.3 M NaCl). In Experiment 1, tests were performed 24 h after subcutaneous injection of the natriuretic/diuretic furosemide and removal of ambient sodium. MK-801 inhibited salt intake by 60% average but did not alter salt palatability, compared with vehicle. In Experiment 2, MK-801 was paired with episodes of rapid-onset (1-h latency) sodium appetite, that is, in response to a combination of furosemide with low-dose captopril, or Furo/Cap. A pairing of MK-801, or its vehicle, with Furo/Cap was performed every other three days, three times. In a post-pairing trial, conducted 3 days after the last pairing, MK-801 history did not alter salt palatability in response to Furo/Cap, although it blocked, as expected, salt intake sensitization. In Experiment 3, MK-801 inhibited food intake in animals deprived of food for 24 h, and the respective meal-associated water intake by 60% average. The results suggest that the inhibitory effect of MK-801 on salt intake sensitization is not dependent on increased salt aversion, but they cannot rule out the participation of a general behavioral inhibition on such an effect.

News (Medical) associated with Chidamide

11 Feb 2025

·cerenoscientific.com

Cereno Scientific’s HDACi CS014 has successfully completed part one of its Phase I trial evaluating the safety profile with a single ascending dose (SAD) study

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that drug candidate CS014 has completed the first part of two in its Phase I trial in healthy volunteers without any safety concerns. CS014 is a novel histone deacetylase (HDAC) inhibitor with disease-modifying potential being developed for the rare disease idiopathic pulmonary fibrosis (IPF). The Phase I trial intends to evaluate the safety profile of CS014 in humans and is divided into two parts – a single ascending dose part (SAD) and a multiple ascending dose part (MAD). Part two of the trial (MAD) is currently ongoing according to plan and the Phase I trial is expected to be completed in mid-2025. HDACi CS014 has the potential to transform the treatment landscape of IPF. Drug candidate CS014 is a new chemical entity that acts through HDACi with strong vascular remodeling effects and disease-modifying potential as seen in preclinical studies. The potential of the HDACis has been demonstrated through preclinical studies including reversal of pathological remodeling of pulmonary vessels and anti-fibrotic effects in an animal model of PAH, as well as in vivo anti-thrombotic effects across a broad range of vasculature. These properties align with the key disease mechanisms of idiopathic pulmonary fibrosis (IPF) and addresses significant unmet medical needs. The HDACi CS014 has a safety and efficacy profile that is consistent with the significant medical needs remaining despite current IPF treatments. Part one of the Phase I trial of CS014 conducted by our CRO partner CTC in Uppsala explored the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses (SAD) of CS014 in 30 patients. This first part of the trial has successfully been completed with results showing that CS014 exhibited an acceptable safety profile supporting its potential for further clinical development. “We are pleased with the progress of the CS014 Phase I trial and eagerly anticipate its completion in mid-2025. The successful completion of the single ascending dose (SAD) part provides a strong initial validation of HDACi CS014s favorable safety profile,” said Rahul Agrawal, CMO & Head of R&D of Cereno Scientific. “We believe that our novel HDACi CS014 has the potential to become an important treatment meeting high unmet clinical needs in the rare disease IPF. There is a void in the market for safe and well-tolerated novel drugs with a profile addressing the underlying pathophysiology of the IPF disease and its progression. CS014 aims to be a safe, well-tolerated oral drug with disease-modifying capacity and, as such, targets a large market potential,” said Sten R. Sörensen, CEO of Cereno Scientific. The Phase I trial is an open-label, first-in-man trial designed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers. The Phase I trial of CS014 will involve approximately 48 subjects and is expected to be completed mid-2025 whereafter top-line results can be shared after data analysis has been conducted. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About CS104 HDAC inhibitor CS014 is a new chemical entity with a multi-modal mechanism of action as an epigenetic modulator, under development for idiopathic pulmonary fibrosis (IPF). An ongoing Phase I trial evaluating the safety, tolerability, pharmacokinetics, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending oral doses of CS014 in healthy volunteers is expected to conclude in mid-2025. Preclinical studies of HDAC inhibitors show that these drugs can reverse fibrosis in models of IPF. Studies also show that these drugs prevent the pathological remodeling of pulmonary vessels that ultimately leads to pulmonary hypertension in many IPF patients. Preclinical studies of CS014 have demonstrated an effect on reversal of fibrosis and a dose-dependent beneficial effect on pathological vascular remodeling in an established model of PAH. Together, these findings indicate that CS014 has the potential to address the underlying pathophysiology behind the development of IPF. CS014 has demonstrated, in preclinical studies, the ability to regulate platelet activity, local fibrinolysis, and clot stability, helping to prevent thrombosis without increasing the risk of bleeding. This supports CS014's potential to address key unmet needs in IPF patients. Cereno’s HDAC inhibitor portfolio, capitalizing on the principle of epigenetic modulation, comprises Cereno’s lead drug candidate CS1 in Phase II and CS014. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 1Clinical ResultPhase 2

27 Dec 2024

·cerenoscientific.com

Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that 9 additional patients have entered its Expanded Access Program (EAP) with drug candidate CS1 in rare disease pulmonary arterial hypertension (PAH). In total, the EAP now includes 10 patients with the possibility of more patients being included in the coming months. The additional data collected on the patients in the EAP will strengthen the long-term safety and efficacy documentation of CS1 and support regulatory interactions for future clinical trials. “We are very pleased to see the high interest from patients and physicians to continue with the treatment of CS1 after the completed Phase IIa study,” said Sten R. Sörensen, CEO, Cereno Scientific. “From a drug development perspective, it is very valuable for us to be able to collect long-term clinical data on CS1 as we move forward with our plans for the next clinical program.” Drug candidate CS1 has been approved by the FDA for an Expanded Access Program as an extension of the Phase IIa trial in PAH. This program allows patients who have completed the Phase IIa trial to continue CS1 treatment if deemed suitable by physicians in the study. Through the recently entered collaboration with innovative medical company Fluidda, their non-invasive imaging technology called Functional Respiratory Imaging (FRI) will be used on certain patients enrolled in the EAP to visualize how long-term use of CS1 influences changes in pulmonary arteries. The EAP, an FDA-approved protocol, enables Cereno to obtain valuable long-term safety and efficacy data of CS1 in PAH patients supporting required regulatory interactions and planning future Phase IIb or pivotal Phase III trials. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 732- 33 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About CS1 Drug candidate CS1 is an HDAC inhibitor (HDACi) that works through epigenetic modulation, being developed as a safe, effective and disease-modifying treatment for the rare disease pulmonary arterial hypertension (PAH). CS1 targets the root mechanism of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries. In a Phase IIa study, CS1 successfully met the primary endpoint of safety and tolerability. CS1 further showed compelling positive impact on exploratory clinical efficacy parameters over the 12-week treatment period. The Phase IIa data, together with preclinical data from the HDACi program, directly demonstrates the HDACi program’s dose-dependent positive impact on reverse remodeling in small lung arteries. This provides a basis of assumption that CS1 may act with disease-modifying capacity in PAH. In preclinical cardiovascular disease models, HDAC inhibitors have also shown anti-fibrotic, anti-inflammatory, pulmonary pressure-reducing, and anti-thrombotic effects. CS1’s unique efficacy profile aligns well with the underlying mechanisms of disease that drives the progression of PAH, positioning it to address the critical unmet need for more effective treatment options. The goal of CS1's development is to enhance and extend life for patients with PAH. CS1 is part of Cereno’s HDACi portfolio, untapping the potential of epigenetic modulation in rare cardiovascular and pulmonary diseases. CS1 has been granted orphan drug status in both the US and EU. CS1 has been approved by the FDA for an Expanded Access Program (EAP) as an extension of the Phase IIa trial in PAH, which enables Cereno to obtain valuable long-term safety and efficacy data of CS1 in PAH patients. Ten patients are currently enrolled in the program, which allows patients who have completed the Phase IIa trial to continue CS1 treatment if deemed suitable by physicians in the study. Through a collaboration with innovative medical company Fluidda, their non-invasive imaging technology called Functional Respiratory Imaging (FRI) will be used on certain patients enrolled in the EAP to visualize how long-term use of CS1 influences changes in pulmonary arteries. The data obtained by the EAP supports required regulatory interactions and planning future Phase IIb or pivotal Phase III trials. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Phase 1Clinical ResultOrphan Drug

20 Dec 2024

·cerenoscientific.com

Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated

20 Dec 2024 07:00Regulatory Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announced on 11 November 2024 that the Company has entered into a financing agreement (the “Financing Agreement”) with Fenja Capital II A/S and the US-based investor Arena Investors, LP (the “Financiers”) securing loan financing of at least 250 MSEK. The Financing Agreement is divided into three components: (i) a cash loan in two tranches totaling 175 MSEK (the “Loan”), (ii) the issue of convertible loans of 75 MSEK to the Financiers (the “Convertibles”), and (iii) the issue without consideration of 5,749,017 warrants to the Financiers (the “Warrants”). The Company today announce that the Convertibles and the Warrants have been registered with the Swedish Companies Registration Office and that the transfer of the Warrants to the Financiers’ custody accounts has been initiated. Completed registration and ongoing delivery The Company hereby announces that the Convertibles and the Warrants have been registered with the Swedish Companies Registration Office and that the delivery of the Warrants following their connection to Euroclear has been initiated to the custody accounts designated by the Financiers. Main terms of the Convertibles, the Warrants and the Loan The convertible loans of 75 MSEK is represented by convertible promissory notes in the nominal amount of SEK 1 per Convertible. The Convertibles will be due for repayment on 30 April 2026 (the "Maturity Date"), unless Conversion has occurred before that date. The rate of interest on the Convertibles are calculated quarterly and determined at the percentage rate per annum which is the aggregate of STIBOR90 with an additional 11 percentage points. The Company has a right but no obligation to repay the Convertibles, in whole or in part, at any time prior to the Maturity Date without separate costs. In connection with any premature repayment, accrued interest of the amount so prepaid should be paid at the same time. During the term of the Convertibles, the Financiers may demand conversion of all or part of the Convertibles into new B shares in the Company at a conversion price fixed at SEK 6.09. Presuming full conversion of the Convertibles the number of shares in Cereno Scientific will increase by 12,315,270 B-shares and the share capital will increase by SEK 1,231,527 corresponding to a dilution effect of approximately 4.19 per cent of the currently outstanding shares in the company and approximately 4.10 per cent of the currently outstanding votes in the company. In relation to the Warrants, the Financiers are entitled to subscribe for one new B share for each Warrant at a subscription price of SEK 6.82 per B share during the term of the Warrants (up to and including 8 November 2029). Exercise of the Warrants can be done during the whole term of the Warrants. Upon full exercise of the Warrants, the company will receive additional issue proceeds of approximately 39.2 MSEK. Presuming full exercise of the Warrants, the number of shares in Cereno Scientific will increase by 5,749,017 B-shares and the share capital will increase by SEK 574,901.70 corresponding to a dilution effect of approximately 2.00 per cent of the currently outstanding shares in the company and 1.96 per cent of the currently outstanding votes in the company. The Loan is divided into two tranches where Tranche 1 consists of a cash loan of 125 MSEK which was paid out in connection with the signing of the Financing Agreement. Tranche 2 consists of a cash loan of 50 MSEK and is conditional upon the Company having received approval by the FDA regarding CS1 for a phase IIB study or a pivotal study for phase III as well as certain additional financial conditions being fulfilled. The Loan was subject to a customary setup fee amounting to approximately 3,87 per cent of the funding under the Financing Agreement. Parts of Tranche 1 of the Loan have been used to repay the currently outstanding loan to Fenja of approximately 91 MSEK. The interest rate of the Loan under the Financing Agreement is fixed annually starting at the time of payment and bears an annual interest rate set at the percentage rate per annum which is the sum of STIBOR plus 11 percentage points. Repayment of the Loan (both Tranches, if applicable) shall be made on 30 April 2026. Further fundamental information about the Convertibles, the Warrants and the Financing Agreement can be found in the press release of 11 November 2024: Press release | Cereno Scientific. For further information, please contact: Eva Jagenheim, CFO Email: eva.jagenheim@cerenoscientific.com Phone: +46 70 492 35 63 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as a safe, effective and disease modifying treatment for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. HDACi CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 employs a multi-modal mechanism of action as an epigenetic modulator, targeting key unmet needs in patients with rare disease Idiopathic Pulmonary Fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information at www.cerenoscientific.com. Read PDF Share

Phase 1Phase 2Clinical Result

100 Deals associated with Chidamide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Chidamide	L01XX	DB06334

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diffuse Large B-Cell Lymphoma	China	Shenzhen Chipscreen Biosciences Co., Ltd.	24 Apr 2024
Adult T-Cell Leukemia-Lymphoma	Japan	Meiji Seika Pharma Co., Ltd.	23 Jun 2021
Breast Cancer	China	Shenzhen Chipscreen Biosciences Co., Ltd.	20 Nov 2019
Peripheral T-Cell Lymphoma	China	Shenzhen Chipscreen Biosciences Co., Ltd.	23 Dec 2014

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Microsatellite Stable Colorectal Carcinoma	Phase 3	China	Shenzhen Chipscreen Biosciences Co., Ltd.	27 Nov 2024
Metastatic Microsatellite Stable Colorectal Carcinoma	Phase 3	China	Sun Yat-Sen University	01 Mar 2023
Microsatellite Instability cancer	Phase 3	China	Sun Yat-Sen University	01 Mar 2023
Brain metastases	Phase 3	United States	HUYA Bioscience International LLC	12 Aug 2021
Brain metastases	Phase 3	United States	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Japan	HUYA Bioscience International LLC	12 Aug 2021
Brain metastases	Phase 3	Japan	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Australia	Bristol Myers Squibb Co.	12 Aug 2021
Brain metastases	Phase 3	Australia	HUYA Bioscience International LLC	12 Aug 2021
Brain metastases	Phase 3	Austria	HUYA Bioscience International LLC	12 Aug 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2200058431 (P-henomS/SCOG-P002, ASCO_GI2025) Manual	Phase 2	Pancreatic Cancer Second line	16	Chidamide + Envafolimab + S-1	nrzanfbbqa(ujyqvkxmcb) = yckikuhcen eouumjolpj (fwpsjafgma ) View more	Positive	23 Jan 2025
NCT04661943 (4490Chidamide, ASH2024)	Phase 2	Hepatitis B \| Diffuse Large B-Cell Lymphoma Maintenance	95	Chidamide maintenance therapy	rjlegrwpee(yscukyscji) = neutropenia, anemia, thrombocytopenia rieupsmubb (ynthsggbka )	Positive	09 Dec 2024
NCT04661943 (4490Chidamide, ASH2024)	Phase 2	Hepatitis B \| Diffuse Large B-Cell Lymphoma Maintenance	95	Chidamide (Observation group)		Positive	09 Dec 2024
ASH2024	Not Applicable	Relapsing acute myeloid leukemia	-	Chidamide	hrwrzpyktv(jmzkctbwhj) = one patient experienced grade 3/4 diarrhea ztymqkfajq (nsabsaotgm ) View more	-	07 Dec 2024
ASH2024	Not Applicable	Acute Myeloid Leukemia	-	VAC regimen	ypoftzrpih(nkjgavvgvf) = cfusgfvqbf jxsgqonfnu (jtiznhadxx ) View more	-	07 Dec 2024
ASH2024	Not Applicable	Acute Myeloid Leukemia	-	VA regimen	ypoftzrpih(nkjgavvgvf) = lasojefmox jxsgqonfnu (jtiznhadxx ) View more	-	07 Dec 2024
NCT02718066 (HBI-8000-302, SITC2024) Manual	Phase 1/2	Melanoma	39	HBI-8000 + Nivolumab	nxkasyjxbr(ugpwztkwhb) = qinsazabev lwiyluslkp (zgphnhasid ) View more	Positive	05 Nov 2024
NCT02955589 (Phase 2B Study, CTgov)	Phase 2	Adult T-Cell Leukemia-Lymphoma	23	HBI-8000	jwwfsxjdcs = jfdnsjlhng xwagvhgywc (xcqzxotrry, btlydivnuq - aghldammdj) View more	-	19 Sep 2024
NCT05411380 (ESMO2024) Manual	Phase 2	Hormone receptor positive HER2 negative breast cancer HER2 Negative \| Hormone Receptor Positive	43	Tucidinostatcapecitabine	zrympidfss(nckwcywzkn) = xhaiziylym knsxohjejq (yradahwxyx ) View more	Positive	16 Sep 2024
ChiCTR2400080783 (B-Enefits/SCOG-B001, ESMO2024) Manual	Phase 2	Biliary Tract Neoplasms First line	32	Envafolimabchidamide	afxtwanzsb(xurrxwakwv) = dxfsigbnjq vmdmjkkbzf (hyvjbxkobe ) View more	Positive	16 Sep 2024
NCT03268889 (Pubmed \| Front Immunol) Manual	Not Applicable	Immunoblastic Lymphadenopathy	66	Chidamide + CHOP	fjogkjkprb(mvnovtxksa) = eygcxgsjgd nqnnnqcotb (oubjyabklk ) View more	Positive	20 Aug 2024
NCT03268889 (Pubmed \| Front Immunol) Manual	Not Applicable	Immunoblastic Lymphadenopathy	66	CHOP alone	fjogkjkprb(mvnovtxksa) = zkjqsdsflb nqnnnqcotb (oubjyabklk ) View more	Positive	20 Aug 2024
NCT04231448 (DEB, ASCO2024) Manual	Phase 3	Diffuse Large B-Cell Lymphoma First line MYC expression \| BCL2 expression	423	Tucidinostat plus R-CHOP	ftigmadxxl(mddlqqfpdj) = wmyvzzlscf jxfelucqjk (kokfrnpwoh, 48.9 - 67.6) View more	Positive	02 Jun 2024
NCT04231448 (DEB, ASCO2024) Manual	Phase 3		423	Placebo plus R-CHOP	ftigmadxxl(mddlqqfpdj) = mvdeuwfeqg jxfelucqjk (kokfrnpwoh, 35.7 - 56.1) View more	Positive	02 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis